Page last updated: 2024-11-05

thalidomide and Hemoptysis

thalidomide has been researched along with Hemoptysis in 1 studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Hemoptysis: Expectoration or spitting of blood originating from any part of the RESPIRATORY TRACT, usually from hemorrhage in the lung parenchyma (PULMONARY ALVEOLI) and the BRONCHIAL ARTERIES.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Abrantes, J1
Fernandes, C1
Vieira, CL1

Other Studies

1 other study available for thalidomide and Hemoptysis

ArticleYear
Pulmonary arteriovenous malformation in hereditary haemorrhagic telangiectasia.
    BMJ case reports, 2019, Feb-09, Volume: 12, Issue:2

    Topics: Angiogenesis Inhibitors; Argon Plasma Coagulation; Arteriovenous Malformations; Bevacizumab; Endosco

2019